Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Bladder Cancer

  Free Subscription


17.09.2018

1 ACS Nano
1 Adv Radiat Oncol
2 Anticancer Res
1 BMJ Case Rep
1 Cancer Invest
1 Cancer Manag Res
1 Cell Mol Biol (Noisy-le-grand)
1 Cell Physiol Biochem
1 Clin Genitourin Cancer
1 Diagn Interv Radiol
1 Eur Heart J
1 Eur Urol
1 Eur Urol Focus
1 Exp Ther Med
1 Gene
2 Int J Mol Sci
1 J Cancer
1 J Cancer Res Ther
1 J Cell Biochem
1 J Clin Oncol
1 J Int Med Res
2 Medicine (Baltimore)
1 Minerva Urol Nefrol
1 Ocul Immunol Inflamm
2 Oncol Lett
1 Oncotarget
1 Pan Afr Med J
1 Prog Urol
1 Prostate
1 Theranostics
8 Transl Androl Urol
1 Vasc Endovascular Surg
1 Virchows Arch
1 World J Urol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    ACS Nano

  1. DAVIS RM, Kiss B, Trivedi DR, Metzner TJ, et al
    Surface-Enhanced Raman Scattering Nanoparticles for Multiplexed Imaging of Bladder Cancer Tissue Permeability and Molecular Phenotype.
    ACS Nano. 2018 Sep 11. doi: 10.1021/acsnano.8b03217.
    PubMed     Text format     Abstract available


    Adv Radiat Oncol

  2. TONG Y, Udupa JK, Wang C, Chen J, et al
    Radiomics-guided therapy for bladder cancer: Using an optimal biomarker approach to determine extent of bladder cancer invasion from t2-weighted magnetic resonance images.
    Adv Radiat Oncol. 2018;3:331-338.
    PubMed     Text format     Abstract available


    Anticancer Res

  3. LEA MA, Kim H, desBORDES C
    Effects of Biguanides on Growth and Glycolysis of Bladder and Colon Cancer Cells.
    Anticancer Res. 2018;38:5003-5011.
    PubMed     Text format     Abstract available

  4. TSAI TH, Wang YM, Chang WS, Tsai CW, et al
    Association of Matrix Metalloproteinase-8 Genotypes with the Risk of Bladder Cancer.
    Anticancer Res. 2018;38:5159-5164.
    PubMed     Text format     Abstract available


    BMJ Case Rep

  5. JALLAD S, Ghani S, Omar MA, Motiwala H, et al
    Isolated bladder schwannoma: a rare presentation.
    BMJ Case Rep. 2018;2018.
    PubMed     Text format     Abstract available


    Cancer Invest

  6. MORIZAWA Y, Miyake M, Shimada K, Hori S, et al
    Correlation Of Immune Cells And Cytokines In The Tumor Microenvironment With Elevated Neutrophil-To-Lymphocyte Ratio In Blood: An Analysis Of Muscle-Invasive Bladder Cancer.
    Cancer Invest. 2018 Sep 10:1-11. doi: 10.1080/07357907.2018.1506800.
    PubMed     Text format     Abstract available


    Cancer Manag Res

  7. DU E, Lu C, Sheng F, Li C, et al
    Analysis of potential genes associated with primary cilia in bladder cancer.
    Cancer Manag Res. 2018;10:3047-3056.
    PubMed     Text format     Abstract available


    Cell Mol Biol (Noisy-le-grand)

  8. YEGIN Z, Aydin O, Koc H, Buyukalpelli R, et al
    Expression profiles of proto-oncogene TWIST1 and tumor metastasis suppressor gene LASS2 in bladder cancer.
    Cell Mol Biol (Noisy-le-grand). 2018;64:66-73.
    PubMed     Text format     Abstract available


    Cell Physiol Biochem

  9. HE RQ, Zhou XG, Yi QY, Deng CW, et al
    Prognostic Signature of Alternative Splicing Events in Bladder Urothelial Carcinoma Based on Spliceseq Data from 317 Cases.
    Cell Physiol Biochem. 2018;48:1355-1368.
    PubMed     Text format     Abstract available


    Clin Genitourin Cancer

  10. FISHER MD, Shenolikar R, Miller PJ, Fenton M, et al
    Treatment Patterns and Outcomes in Stage IV Bladder Cancer in a Community Oncology Setting: 2008-2015.
    Clin Genitourin Cancer. 2018 Aug 11. pii: S1558-7673(18)30141.
    PubMed     Text format     Abstract available


    Diagn Interv Radiol

  11. RAYN KN, Hale GR, Bloom JB, Gold SA, et al
    Incidental bladder cancers found on multiparametric MRI of the prostate gland: a single center experience.
    Diagn Interv Radiol. 2018;24:316-320.
    PubMed     Text format     Abstract available


    Eur Heart J

  12. FUJIMOTO D, Mochizuki Y, Nakagiri K, Shite J, et al
    Unusual rapid progression of non-bacterial thrombotic endocarditis in a patient with bladder cancer despite undergoing intensification treatment with rivaroxaban for acute venous thromboembolism.
    Eur Heart J. 2018 Sep 9. pii: 5093360. doi: 10.1093.
    PubMed     Text format    


    Eur Urol

  13. TAN TZ, Rouanne M, Tan KT, Huang RY, et al
    Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.
    Eur Urol. 2018 Sep 10. pii: S0302-2838(18)30619.
    PubMed     Text format     Abstract available


    Eur Urol Focus

  14. SVATEK RS, Tangen C, Delacroix S, Lowrance W, et al
    Background and Update for S1602 "A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-naive High-grade Non-muscle-invasive Bladder Cancer.
    Eur Urol Focus. 2018 Sep 6. pii: S2405-4569(18)30234.
    PubMed     Text format     Abstract available


    Exp Ther Med

  15. ZHOU W, He L, Dai Y, Zhang Y, et al
    MicroRNA-124 inhibits cell proliferation, invasion and migration by targeting CAV1 in bladder cancer.
    Exp Ther Med. 2018;16:2811-2820.
    PubMed     Text format     Abstract available


    Gene

  16. SONG Y, Hu J, Chen Q, Guo J, et al
    Association between vascular endothelial growth factor rs699947 polymorphism and the risk of three major urologic neoplasms (bladder cancer, prostate cancer, and renal cell carcinoma): A meta-analysis involving 11,204 subjects.
    Gene. 2018;679:241-252.
    PubMed     Text format     Abstract available


    Int J Mol Sci

  17. DO MH, To PK, Cho YS, Kwon SY, et al
    Targeting CD46 Enhances Anti-Tumoral Activity of Adenovirus Type 5 for Bladder Cancer.
    Int J Mol Sci. 2018;19.
    PubMed     Text format     Abstract available

  18. LI CF, Shen KH, Chien LH, Huang CH, et al
    Proteomic Identification of the Galectin-1-Involved Molecular Pathways in Urinary Bladder Urothelial Carcinoma.
    Int J Mol Sci. 2018;19.
    PubMed     Text format     Abstract available


    J Cancer

  19. HAN C, Mengual L, Kang B, Lozano JJ, et al
    Validation of Urine-based Gene Classifiers for Detecting Bladder Cancer in a Chinese Study.
    J Cancer. 2018;9:3208-3215.
    PubMed     Text format     Abstract available


    J Cancer Res Ther

  20. WADHWA N, Mathew BB, Tandon S, Biju VG, et al
    Assessment of microsatellite instability for screening bladder cancer in high-risk population.
    J Cancer Res Ther. 2018;14:916-920.
    PubMed     Text format     Abstract available


    J Cell Biochem

  21. CHEN X, Liu M, Meng F, Sun B, et al
    The long noncoding RNA HIF1A-AS2 facilitates cisplatin resistance in bladder cancer.
    J Cell Biochem. 2018 Sep 14. doi: 10.1002/jcb.27327.
    PubMed     Text format     Abstract available


    J Clin Oncol

  22. MOSSANEN M, Caldwell J, Sonpavde G, Lehmann LS, et al
    Treating Patients With Bladder Cancer: Is There an Ethical Obligation to Include Smoking Cessation Counseling?
    J Clin Oncol. 2018 Sep 13:JCO1800577. doi: 10.1200/JCO.18.00577.
    PubMed     Text format    


    J Int Med Res

  23. HE L, Li S, Zheng C, Wang C, et al
    Rare symptomatic bladder leiomyoma: case report and literature review.
    J Int Med Res. 2018;46:1678-1684.
    PubMed     Text format     Abstract available


    Medicine (Baltimore)

  24. BAO Y, Tu X, Chang T, Qiu S, et al
    The role of fluorescence in situ hybridization to predict patient response to intravesical Bacillus Calmette-Guerin therapy for bladder cancer: A diagnostic meta-analysis and systematic review.
    Medicine (Baltimore). 2018;97:e12227.
    PubMed     Text format     Abstract available

  25. WANG H, Ding W, Jiang G, Gou Y, et al
    EORTC risk tables are more suitable for Chinese patients with nonmuscle-invasive bladder cancer than AUA risk stratification.
    Medicine (Baltimore). 2018;97:e12006.
    PubMed     Text format     Abstract available


    Minerva Urol Nefrol

  26. MANTICA G, Simonato A, Du Plessis DE, Maffezzini M, et al
    The pathologist's role in the detection of rare variants of bladder cancer and analysis of the impact on incidence and type detection.
    Minerva Urol Nefrol. 2018 Sep 10. pii: S0393-2249.18.03175.
    PubMed     Text format     Abstract available


    Ocul Immunol Inflamm

  27. LLORENC V, Mesquida M, Molins B, Gonzalez-Martin J, et al
    Bacillus Calmette-Guerin Infection and Cytotoxicity in the Retinal Pigment Epithelium.
    Ocul Immunol Inflamm. 2018;26:786-792.
    PubMed     Text format     Abstract available


    Oncol Lett

  28. WANG H, Hu Z, Chen L
    Enhanced plasma miR-26a-5p promotes the progression of bladder cancer via targeting PTEN.
    Oncol Lett. 2018;16:4223-4228.
    PubMed     Text format     Abstract available

  29. PENG L, Pan P, Chen J, Yu X, et al
    A tetracycline-inducible CRISPR/Cas9 system, targeting two long non-coding RNAs, suppresses the malignant behavior of bladder cancer cells.
    Oncol Lett. 2018;16:4309-4316.
    PubMed     Text format     Abstract available


    Oncotarget

  30. MURAKAMI T, Yamamoto CM, Akino T, Tanaka H, et al
    Bladder cancer detection by urinary extracellular vesicle mRNA analysis.
    Oncotarget. 2018;9:32810-32821.
    PubMed     Text format     Abstract available


    Pan Afr Med J

  31. YOUSSEF K, Dembele ON, Idriss Z, Elsayegh H, et al
    [Bladder leiomyosarcoma: about 3 cases].
    Pan Afr Med J. 2018;30:19.
    PubMed     Text format     Abstract available


    Prog Urol

  32. PIGNOT G, Houede N, Roumiguie M, Audenet F, et al
    [ypT0N0 after neoadjuvant chemotherapy and cystectomy for muscle-invasive bladder cancer: Incidence and prognosis. A review from the Bladder group of the French Committee of Oncology].
    Prog Urol. 2018 Sep 8. pii: S1166-7087(18)30181.
    PubMed     Text format     Abstract available


    Prostate

  33. GHORBANMEHR N, Gharbi S, Korsching E, Tavallaei M, et al
    miR-21-5p, miR-141-3p, and miR-205-5p levels in urine-promising biomarkers for the identification of prostate and bladder cancer.
    Prostate. 2018 Sep 7. doi: 10.1002/pros.23714.
    PubMed     Text format     Abstract available


    Theranostics

  34. YEON A, You S, Kim M, Gupta A, et al
    Rewiring of cisplatin-resistant bladder cancer cells through epigenetic regulation of genes involved in amino acid metabolism.
    Theranostics. 2018;8:4520-4534.
    PubMed     Text format     Abstract available


    Transl Androl Urol

  35. OTTO W
    Stage T1 bladder cancer: historic background and latest tracks for its demystification.
    Transl Androl Urol. 2018;7:760-763.
    PubMed     Text format    

  36. CULINE S, Allory Y, Pfister C
    Refining the use of neoadjuvant chemotherapy in locally advanced bladder cancer: from conviction to optimization.
    Transl Androl Urol. 2018;7:757-759.
    PubMed     Text format    

  37. THIRUTHANEESWARAN N, Choudhury A
    Exploring trends in advanced bladder cancer using the NCDB: turning data into information and information into insight.
    Transl Androl Urol. 2018;7:754-756.
    PubMed     Text format    

  38. OSZCZUDLOWSKI M, Dobruch J
    Prediction of progression to muscle-invasive disease in patients with high-risk bladder cancer.
    Transl Androl Urol. 2018;7:749-751.
    PubMed     Text format    

  39. MOSCHINI M, Zamboni S, Mattei A, Martini A, et al
    Evaluating the role of neoadjuvant chemotherapy in bladder cancer patients with occult lymph node metastases.
    Transl Androl Urol. 2018;7:742-744.
    PubMed     Text format    

  40. SOMANI BK
    Bladder utility symptom scale: a new patient reported outcome measure for health-related quality of life in bladder cancer.
    Transl Androl Urol. 2018;7:740-741.
    PubMed     Text format    

  41. PAN CC
    The value of molecular markers in classification and prediction of progression in non-muscle-invasive bladder cancer.
    Transl Androl Urol. 2018;7:736-739.
    PubMed     Text format    

  42. JOSHI SS, Handorf ER, Smaldone MC, Geynisman DM, et al
    What can the National Cancer Database tell us about disparities in advanced bladder cancer outcomes?
    Transl Androl Urol. 2018;7:732-735.
    PubMed     Text format    


    Vasc Endovascular Surg

  43. LAREYRE F, Reverso-Meinietti J, Carboni J, Gaudart A, et al
    Mycotic Aortic Aneurysm and Infected Aortic Graft After Intravesical Bacillus Calmette-Guerin Treatment for Bladder Cancer.
    Vasc Endovascular Surg. 2018 Sep 13:1538574418800128.
    PubMed     Text format     Abstract available


    Virchows Arch

  44. ZAVALISHINA L, Tsimafeyeu I, Povilaitite P, Raskin G, et al
    RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer.
    Virchows Arch. 2018 Sep 13. pii: 10.1007/s00428-018-2453.
    PubMed     Text format     Abstract available


    World J Urol

  45. MOSSANEN M, Chu A, Smith AB, Gore JL, et al
    Inferring bladder cancer research prioritization from patient-generated online content.
    World J Urol. 2018 Sep 10. pii: 10.1007/s00345-018-2479.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: